Long-acting therapies could reduce schizophrenia relapse

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

  1. Liebermann JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996;57 Suppl 11:68-71
  2. NICE Clinical Guideline 178. Psychosis and schizophrenia in adults: prevention and management. 2014. Available at: https://www.nice.org.uk/guidance/cg178
  3. Barnes TR et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620
  4. Lehman et al. APA practice guideline for the treatment of patients with schizophrenia. 2nd edition, 2010
  5. DeQuardo JR, Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res. 1998;32:229-42
  6. Parks J. Clinical strategies to promote medication adherence. Available at: www.thenationalcouncil.org/wp-content/uploads/2020/04/Clinical-Strategies-to-Promote-Medication-Adherence-6.20.18.pdf?daf=37SateTbd56
  7. Velligan DI et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70:1-46
  8. Keepers GA et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177:868-72
  9. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67:15-8
  10. Kane JM et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64:5-19
  11. Patel MX et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12:237-44
  12. Kim HO et al. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry. 2020;19:1
  13. Citrome L et al. P.561 Barriers to the use of long-acting injectable antipsychotics in patients with schizophrenia: a survey to understand clinician educational needs. Eur Neuropsychopharmacol. 2020;40:S318-9
  14. Caroli F. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165-71
  15. Weiden PJ. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76:684-9
  16. Haque SF, D’Souza A. Motivational interviewing: the RULES, PACE, and OARS. Current Psychiatry. 2019;18:27-8
Du lämnar Progress in Mind Sverige
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Den här informationen är endast avsedd för hälso- och sjukvårdspersonal
Register for access to Progress in Mind in your country